Post by
BioTeck on Jun 07, 2022 6:13pm
Dose of reality
For those who are looking at things positively. May 2018, we got green light to start clinical trial. So 4 long years later we have 3 people out of 7 with cell pouches. That is less than 1 person per year. The study is slated for preliminary completion in July 2022. So obviously that won't be happening. If past performance is any indication of future performance we still have 3 more years to go before they complete the study. Patient 7 seems to be harder to find than Waldo. Is it a surprise given our management? They managed to do 2 years of secret collaboration with Sanofi/Evotec. They have secret collaborations with 2 other Pharma's which everyone probably already knows about. If spill wasn't such a tool and released news when it happens instead of signing nonhdisclosures and sitting on it and letting it slowly leak through his various IR, we'd be in much better shape. He has zero business acumen and belongs in the lab and the lab only. This year we are on the TSX, so I am looking forward to the voting results. See how close we are to get rid of the dead weight that plagues this stock. So those wondering why the stock isn't moving it's because there is years of time remaining before anything happens that COULD lift the stock. Remember it could also TANK it if the bigger pouch doesn't do as promised. https://clinicaltrials.gov/ct2/show/NCT03513939
Comment by
Stockfshr on Jun 07, 2022 8:55pm
Bio, Is there anything stopping the company from entering a partnership arangement with a company other than Evotec with regards to T1D? Or for Thyroid or Hemophilia A for that matter although early in their development cycle? After all, we seem to be one of the few games left in this space.